ERGIC3: A Potential Drug Target for Neurodegenerative Diseases

Target Name: ERGIC3

NCBI ID: G51614

ERGIC3

ERGIC3: A Potential Drug Target for Neurodegenerative Diseases

ERGIC3, also known as ERGIC and golgi 3, transcript variant 2, is a protein that is expressed in the endoplasmic reticulum and is involved in the formation of the endoplasmic reticulum-associated vesicle (ERV), which is a structure that transports proteins to the plasma membrane for secretion. ERGIC3 is a key component of the ERV formation process and has been identified as a potential drug target in the field of neurodegenerative diseases.

The ERGIC3 protein is composed of two main subunits, known as ERGIC3A and ERGIC3B. ERGIC3A is the N-terminus subunit, which contains a 150 amino acid residue that is involved in the formation of the ERV. ERGIC3B is the C-terminus subunit, which contains a 200 amino acid residue that is involved in the formation of the ERV.

The ERGIC3 protein is expressed in a variety of tissues, including the brain, where it is found in the endoplasmic reticulum, the pancreas, where it is found in the endoplasmic reticulum and the plasma membrane, and the gut, where it is found in the endoplasmic reticulum and the plasma membrane. It is also expressed in various cell types, including neurons, astrocytes, and microglia.

ERGIC3 is involved in the formation of the ERV, which is a structure that transports proteins to the plasma membrane for secretion. The ERV is a specialized vesicle that is formed by the fusion of the endoplasmic reticulum and the cytoplasm. delivery of proteins to the plasma membrane, where they can be targeted to specific cell types and functions.

ERGIC3 is a key component of the ERV formation process. It is formed by the fusion of the endoplasmic reticulum and the cytoplasm, and it is involved in the formation of the ERV by interacting with various cellular structures, including the transmembrane protein known as T- shirt and the cytoskeleton protein known as microtubules.

ERGIC3 has been identified as a potential drug target in the field of neurodegenerative diseases. Because it plays a key role in neurodegenerative diseases, such as Alzheimer's disease, studies have found that ERGIC3 activity is evident in the brains of patients. reduce. In addition, studies have shown that ERGIC3 activity may be related to neuronal survival and apoptosis. Therefore, ERGIC3 is considered a potential drug target and can be used as a new target for the treatment of neurodegenerative diseases.

In addition, the activity of ERGIC3 is also related to synaptic transmission of neurons. Research shows that ERGIC3 plays an important role in synaptic transmission of neurons and is closely related to the efficiency of synaptic transmission of neurons. Therefore, ERGIC3 can serve as a potential drug target for the treatment of neurodegenerative diseases such as Alzheimer's disease.

ERGIC3 is also an important subject of research, and scientists have been exploring its role in the nervous system. Research shows that ERGIC3 plays an important role in the nervous system and is related to neuronal survival and apoptosis. In addition, ERGIC3 is also related to synaptic transmission of neurons and plays an important role in neurons.

Overall, ERGIC3 is a very important protein that plays an important role in the nervous system. Because it plays a key role in neurodegenerative diseases and is associated with neuronal survival and apoptosis, ERGIC3 is a potential drug target as a treatment

Protein Name: ERGIC And Golgi 3

Functions: Possible role in transport between endoplasmic reticulum and Golgi. Positively regulates trafficking of the secretory proteins SERPINA1/alpha1-antitrypsin and HP/haptoglobin (PubMed:31142615)

The "ERGIC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERGIC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets